title: Improved detection of breast cancer on FDG-PET cancer screening using breast positioning device.
abstract: OBJECTIVE
  The aim of this study was to investigate the detection rate of breast cancer by positron emission tomography cancer screening using a breast positioning device.
  
  
  METHODS
  Between January 2004 and January 2006, 1,498 healthy asymptomatic individuals underwent cancer screening by fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) at our institution; 660 of 1498 asymptomatic healthy women underwent breast PET imaging in the prone position using the breast positioning device to examine the mammary glands in addition to whole-body PET imaging. All subjects that showed abnormal (18)F-FDG uptake in the mammary glands were referred for further examination or surgery at our institution or a local hospital. Our data were compared with the histopathological findings or findings of other imaging modalities in our institution and replies from the doctors at another hospital.
  
  
  RESULTS
  Of the 660 participants, 7 (1.06%) were found to have breast cancers at a curable stage. All the seven cancers were detected by breast PET imaging, but only five of these were detected by whole-body PET imaging; the other two were detected by breast PET imaging using the breast positioning device.
  
  
  CONCLUSIONS
  In cancer screening, prone breast imaging using a positioning device may help to improve the detection rate of breast cancer. However, overall cancer including mammography and ultrasonography screening should be performed to investigate the false-negative cases and reduce false-positive cases. The effectiveness of prone breast PET imaging in cancer screening should be investigated using a much larger number of cases in the near future.
authors.affiliation: Division of Nuclear Medicine, PET Center and Department of Radiology, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, Fukuoka 830-0011, Japan. hayato@med.kurume-u.ac.jp
authors.forename: Hayato
authors.initials: H
authors.lastname: Kaida
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Ishibashi
authors.forename: Teruhiko
authors.initials: T
authors.lastname: Fujii
authors.forename: Seiji
authors.initials: S
authors.lastname: Kurata
authors.forename: Etsuyo
authors.initials: E
authors.lastname: Ogo
authors.forename: Maki
authors.initials: M
authors.lastname: Tanaka
authors.forename: Naofumi
authors.initials: N
authors.lastname: Hayabuchi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001940:Breast / Q000503:physiopathology; D001943:Breast Neoplasms / Q000175:diagnosis*; D002985:Clinical Protocols; D019544:Equipment Failure Analysis; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000295:instrumentation / Q000379:methods / Q000706:statistics & numerical data; D008875:Middle Aged; D009367:Neoplasm Staging / Q000295:instrumentation / Q000379:methods / Q000706:statistics & numerical data; D009369:Neoplasms / Q000517:prevention & control; D049268:Positron-Emission Tomography / Q000295:instrumentation* / Q000379:methods*; D016684:Prone Position; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D015203:Reproducibility of Results; D016683:Supine Position; D051598:Whole Body Imaging
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18